MARKETS / PTCHF
PHARMACEUTICAL PREPARATIONS · MID CAP
PureTech Health PLC PTCHF
7 fiscal years on record · USD · FY2024 reported · SEC filings only
Growth
USD 4.8M
Revenue, FY2024 · full 7-year series below
Revenue $M
Net income $M
FY2024 · Revenue 4.8 · Net income 53.5
Compound annual growth
Revenue compounded at −13.2% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
575 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2024 · Operating -2818.9% · Net 575.4%
ROE
FY2024 · ROE 12.2%
Each USD of equity produced 12 cents of profit this year.
The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 |
| EBITDA $B | −0.1 | −0.1 | −0.2 | −0.1 | · | · | · |
| Income tax $B | −0.0 | 0.0 | −0.1 | 0.0 | 0.0 | 0.1 | 0.0 |
| Net income $B | 0.1 | −0.1 | −0.1 | −0.1 | 0.0 | 0.4 | −0.0 |
| Free cash flow $B | −0.1 | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 |
| EPS, diluted $ | 0.21 | −0.24 | −0.18 | −0.21 | 0.02 | 1.44 | −0.16 |
| Dividend / sh $ | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · |
| ROE % | 12.2 | −13.1 | −8.9 | −9.6 | 0.9 | 63.0 | · |
| Shares out B | · | 0.27 | 0.28 | 0.29 | 0.29 | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 23 reconciliationsAUDITED
Reconciled in 7 of 19 fiscal years. 53 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onnot stated in the filings
Incorporated inoutside the United States — SEC code X0
Fiscal year endsDecember 31
Data on record since2018